Mindpeak at Handelsblatt Pharma Congress 2026

At this year’s Handelsblatt Live Pharma Congress 2026, our CEO Felix Faber addressed one of the industry’s most pressing challenges: the high failure rate of clinical trials.
In his session, “AI is the Insurance for Your IHC Biomarker Trial,” Felix outlined how AI-enabled pathology and reproducible biomarker analysis can help de-risk oncology drug development earlier and with greater confidence.
Manual, variable tissue analysis remains a major bottleneck in clinical development. Expert-directed AI can detect subtle signals across billions of pixels, enabling consistent biomarker assessment, improved patient stratification, and reduced development risk and cost.
Thank you to Handelsblatt Live and everyone who joined the discussion.
You may also be interested in
Find out more about our AI-based diagnostics


.webp)
